ClinicalTrials.gg
Not yet recruitingNCT07620418CapExchangeUpdated Jun 29, 2026

CapExchange: A Pilot Feasibility Study of a Capacity-Exchange Programme for Mental Health Recovery

An interventional study of CapExchange in Mental Disorder and Psychosocial Rehabilitation, sponsored by EPSM de la Guadeloupe. Not yet recruiting at 1 site in Guadeloupe. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-29.

Sponsored by EPSM de la Guadeloupe · Not applicable, Interventional, and Health services research

Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

CapExchange is a psychosocial rehabilitation programme based on reciprocal exchange of capacities and services between service users and their community environment, grounded in the concepts of circular mutuality and micro-social contribution. This pilot feasibility study aims to assess the feasibility and acceptability of the programme within the Psychosocial Rehabilitation Service of the EPSM de la Guadeloupe, across three sites: the Unité Passerelle, the CATTG Doubs, and the UREPS outpatient unit. A sample of 10 to 15 adult service users with a stabilized mental disorder is targeted. The intervention comprises five weekly group sessions of 75 minutes. Primary measures include the Social Contribution Score (SCS) and the Warwick-Edinburgh Mental Well-being Scale (WEMWBS).

02

Conditions studied

  • Mental Disorder
  • Psychosocial Rehabilitation

Browse trials for

Keywords

  • recovery micro-social contribution pilot study service exchange Guadeloupe
03

In context

Mental Disorders

1,740 studies on the registry are indexed under Mental Disorders; 348 are open to participants now.

This study's planned enrollment of 15 is below the median of 100 across 1,301 interventional studies indexed under Mental Disorders.

Browse Mental Disorders studies →

Lead sponsor

This is the only study on the registry with EPSM de la Guadeloupe as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18 years or over
  • Stabilized mental disorder (no acute episode in the 3 months preceding inclusion)
  • At least one identifiable practical skill exchangeable in a community context
  • Free and to participation

Exclusion criteria

Exclusion Criteria:

  • Severe clinical instability at the time of inclusion
  • Uncontrolled risk behaviour in social interactions
  • Documented inability to engage in a reciprocity-based framework
  • Opposition from legal guardian for service users under legal protection'
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    CapExchange Programme

    Five weekly group sessions of 75 minutes based on reciprocal exchange of capacities and services between service users and their community environment.

    Behavioral: CapExchange

Interventions

  • BehavioralCapExchange

    A structured group programme comprising five weekly sessions of 75 minutes based on reciprocal exchange of capacities and services between service users and their community environment, grounded in the concepts of circular mutuality and micro-social contribution.

06

What researchers measure

Primary outcomes

  1. Recruitment rate

    Proportion of eligible service users agreeing to participate in the programme

    Time frame: 3 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared given the pilot and feasibility nature of this study and the small sample size.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Sep 2027, 8 months later.

Of 666 non-industry interventional studies with no phase under Mental Disorders, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 45. This study's planned 8 months is below that.

Counting every sponsor, half of 680 studies reached it within 29 months; a quarter within 13 and three quarters within 45.

Mental Disorders covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2026
First posted
Jun 2, 2026
StartEst.
Jan 4, 2027
Primary completionEst.
Sep 15, 2027
CompletionEst.
Dec 20, 2027
Last update
Jun 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07620418
Lead sponsor
EPSM de la Guadeloupe
Responsible party
Sponsor
First posted
Jun 2, 2026
Start date
Jan 4, 2027 (estimated)
Primary completion
Sep 15, 2027 (estimated)
Completion
Dec 20, 2027 (estimated)
Last update
Jun 29, 2026

Study contacts

Ilyass EL MAHFOUDI, MD
Contact
ilyass.elmahfoudi@epsm-guadeloupe.fr
+33608342789
Ilyass El Mahfoudi, MD
principal investigator · EPSM Guadeloupe

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion